Stereotaxis (NYSE: STXS) revenue
Stereotaxis reported revenue of $32.4m for fiscal 2025, 20.3% more than in fiscal 2024 ($26.9m). Since fiscal 2016 its revenue has grown by 0.7%, an average growth of 0.1% a year.
Stereotaxis has grown its revenue for 2 years in a row, and its best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2022, −19.6%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $32.4m | +20.3% | −$22.1m | −68.3% |
| 2024 | $26.9m | +0.5% | −$24.7m | −91.9% |
| 2023 | $26.8m | −4.9% | −$21.8m | −81.6% |
| 2022 | $28.1m | −19.6% | −$18.8m | −66.7% |
| 2021 | $35.0m | +31.5% | −$12.9m | −36.8% |
| 2020 | $26.6m | −7.9% | −$6.7m | −25.2% |
| 2019 | $28.9m | −1.5% | −$4.8m | −16.7% |
| 2018 | $29.3m | −5.8% | −$2.5m | −8.4% |
| 2017 | $31.1m | −3.2% | −$5.9m | −19.0% |
| 2016 | $32.2m | — | −$6.4m | −20.0% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Stereotaxis revenue compared with its sector
By revenue for its latest fiscal year, Stereotaxis ranks 348th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Stereotaxis, 20.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 346th | Precision Biosciences | $34.3m | −50.1% |
| 347th | Orchestra BioMed | $33.5m | 1,169.2% |
| 348th | Stereotaxis | $32.4m | 20.3% |
| 349th | EyePoint | $31.4m | −27.5% |
| 350th | Verastem | $30.9m | 209.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Stereotaxis
- How much revenue did Stereotaxis make in fiscal 2025?
- Stereotaxis reported revenue of $32.4m for fiscal 2025, compared with $26.9m in fiscal 2024.
- How much has the revenue of Stereotaxis grown?
- Between fiscal 2016 and fiscal 2025 it went from $32.2m to $32.4m: 0.7% more, an average growth of 0.1% a year.
- What was the best year for revenue at Stereotaxis?
- Of its last 10 fiscal years, fiscal 2021, with $35.0m.
- Where does Stereotaxis rank in its sector by revenue?
- It ranks 348th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Stereotaxis come from?
- From the annual report (Form 10-K) that Stereotaxis files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Stereotaxis files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Stereotaxis: the Stereotaxis page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.